Prime Medicine (PRME) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PRME SEC filings page.
Prime Medicine (PRME) reported $4.6M in revenue for fiscal year 2025, up 55.3% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Prime Medicine’s development-stage cash model is dominated by research spending, with external financing supporting limited commercial revenue.
In FY2025, research and development was 35x revenue, showing that reported sales remain economically secondary to scientific development. Operating cash flow of-$162.6M nearly matched R&D spending of$160.6M , linking the accounting loss to the core development program rather than a separate cash-conversion problem.
Capital expenditures were only
Financing supplied
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Prime Medicine's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Prime Medicine held $177.7M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $162.6M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Prime Medicine scores 35/100 among other emerging companies.
Prime Medicine had 181M shares outstanding at the end of fiscal year 2025, against 131M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Prime Medicine scores 32/100 among other emerging companies.
Prime Medicine spent $160.6M on research and development in fiscal year 2025, which was 75.4% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Prime Medicine scores 94/100 among other emerging companies.
Prime Medicine reported revenue of $4.6M in fiscal year 2025, against $3.0M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Prime Medicine scores 80/100 among other emerging companies.
Prime Medicine's operations used $162.6M of cash in fiscal year 2025, against $122.9M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Prime Medicine scores 46/100 among other emerging companies.
Prime Medicine's cash, cash equivalents and investments came to $177.7M at the end of fiscal year 2025, against $221.9M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Prime Medicine scores 53/100 among other emerging companies.
Prime Medicine scores -3.32, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($665.7M) relative to total liabilities ($221.9M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Prime Medicine passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Prime Medicine reported a net loss of $201.1M while operations used $162.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Prime Medicine's EBITDA was -$41.5M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 19.4% from the same quarter a year earlier. Against the prior quarter it is up 15.0%.
Prime Medicine reported -$42.1M in net income in Q2 2026. This represents an increase of 19.9% from the same quarter a year earlier. Against the prior quarter it is up 14.3%.
Prime Medicine earned -$0.24 per diluted share (EPS) in Q2 2026. This represents an increase of 41.5% from the same quarter a year earlier. Against the prior quarter it is up 14.3%.
Not reported for Q2 2026.
Cash & Balance Sheet
Prime Medicine recorded an outflow of $41.1M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 4.4% from the same quarter a year earlier. Against the prior quarter it is up 4.3%.
Prime Medicine held $47.5M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Prime Medicine's ROE was -105.8% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 19.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 41.7 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Prime Medicine invested $33.4M in research and development in Q2 2026. This represents a decrease of 19.3% from the same quarter a year earlier. Against the prior quarter it is down 2.1%.
Prime Medicine invested $46K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 97.1% from the same quarter a year earlier. Against the prior quarter it is down 78.5%.
Not reported for Q2 2026.
PRME Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | $838K | $1.2M+486.1% | $1.1M | $1.5M+146.0% | N/A | $209K |
| R&D Expenses | $33.4M-19.3% | $34.1M-15.9% | $34.7M | $44.0M+9.0% | $41.4M-3.9% | $40.6M+7.4% | N/A | $40.3M-1.5% |
| SG&A Expenses | $11.0M-15.8% | $17.4M+31.0% | $14.7M | $11.2M-20.5% | $13.1M+4.1% | $13.3M+19.1% | N/A | $14.1M+34.4% |
| Operating Income | -$43.3M+18.9% | -$50.7M+3.3% | -$48.6M | -$54.0M+0.5% | -$53.4M+4.1% | -$52.4M-8.4% | N/A | -$54.2M-5.4% |
| EBITDA | -$41.5M+19.4% | -$48.8M+3.7% | -$46.7M | -$52.1M+1.1% | -$51.5M+4.8% | -$50.7M-7.8% | N/A | -$52.7M-4.9% |
| Income Tax | N/A | N/A | N/A | N/A | $0+100.0% | $0-100.0% | N/A | $0+100.0% |
| Net Income | -$42.1M+19.9% | -$49.1M+5.3% | -$46.1M | -$50.6M+3.7% | -$52.6M+4.9% | -$51.9M-13.4% | N/A | -$52.5M-3.6% |
| EPS (Basic) | -$0.24+41.5% | -$0.28+30.0% | -$0.24+22.6% | -$0.32+27.3% | -$0.41+10.9% | -$0.40+9.1% | -$0.31+56.9% | -$0.44+20.0% |
| EPS (Diluted) | -$0.24+41.5% | -$0.28+30.0% | -$0.24+22.6% | -$0.32+27.3% | -$0.41+10.9% | -$0.40+9.1% | -$0.31+56.9% | -$0.44+20.0% |
| Diluted Shares (Avg) | 177M+37.2% | 177M+35.3% | N/A | 161M+34.0% | 129M+8.4% | 131M+25.3% | N/A | 120M+30.4% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.
PRME Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $249.0M-10.7% | $294.7M-10.2% | $342.7M+15.2% | $385.0M+15.7% | $279.0M+7.4% | $328.2M+5.4% | $297.5M+53.5% | $332.8M+39.2% |
| Current Assets | $96.8M-20.2% | $137.9M-15.8% | $181.3M-14.4% | $231.4M-6.0% | $121.3M-29.0% | $163.8M-24.8% | $211.9M+48.2% | $246.1M+33.3% |
| Cash & Equivalents | $47.5M-11.8% | $64.1M-30.2% | $63.0M-65.5% | $71.4M-39.5% | $53.8M-3.2% | $91.9M-2.4% | $182.5M+338.9% | $118.0M+168.4% |
| Short-Term Investments | $47.6M | $71.4M | $114.6M | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $209.2M-4.1% | $218.0M-1.5% | $221.9M+53.7% | $223.2M+55.8% | $218.1M+245.6% | $221.2M+227.2% | $144.4M+137.5% | $143.3M+217.1% |
| Current Liabilities | $31.7M-7.1% | $36.3M+5.8% | $37.4M-1.4% | $35.0M-7.5% | $34.1M+64.4% | $34.3M+40.3% | $38.0M-32.7% | $37.9M-3.8% |
| Non-Current Liabilities | $177.5M-3.5% | $181.7M-2.8% | $184.4M+73.3% | $188.2M+78.5% | $184.0M+334.4% | $187.0M+333.0% | $106.4M+2342.0% | $105.4M+1710.4% |
| Total Equity | $39.8M-34.6% | $76.7M-28.3% | $120.9M-21.1% | $161.8M-14.6% | $60.9M-69.0% | $106.9M-56.1% | $153.1M+15.1% | $189.5M-2.3% |
| Retained Earnings | -$979.6M-23.7% | -$937.5M-26.8% | -$888.4M-29.3% | -$842.3M-30.6% | -$791.7M-33.6% | -$739.1M-37.6% | -$687.2M-39.9% | -$644.9M-51.5% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
PRME Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$41.0M+0.9% | -$42.7M+12.6% | -$37.3M-329.3% | -$35.0M-35.2% | -$41.4M+9.0% | -$48.9M+27.8% | $16.2M+137.0% | -$25.9M+33.8% |
| Depreciation & Amortization | $1.8M-4.2% | $1.9M+9.2% | $1.9M+9.3% | $1.9M+20.7% | $1.9M+21.2% | $1.7M+29.3% | $1.7M+37.7% | $1.6M+26.1% |
| Stock-Based Compensation | $4.9M-23.1% | $4.6M-18.3% | N/A | $12.7M+86.7% | $6.3M-21.8% | $5.7M+9.1% | N/A | $6.8M+61.9% |
| Capital Expenditures | $46K-97.1% | $214K-91.2% | $290K-83.8% | $247K-80.7% | $1.6M-17.4% | $2.4M+4.2% | $1.8M-2.7% | $1.3M-56.1% |
| Free Cash Flow | -$41.1M+4.4% | -$42.9M+16.3% | -$37.5M-359.8% | -$35.3M-29.8% | -$43.0M+9.3% | -$51.3M+26.8% | $14.5M+131.6% | -$27.2M+35.4% |
| Investing Cash Flow | $24.0M+767.2% | $43.4M+190.9% | $28.3M-41.3% | -$92.1M-283.0% | $2.8M-59.8% | -$47.7M-28.9% | $48.3M+16.9% | $50.3M+233.3% |
| Financing Cash Flow | $361K+83.2% | $393K-93.5% | $562K+56100.0% | $144.8M+275.9% | $197K+462.9% | $6.0M-96.2% | $1K-99.5% | $38.5M+12011.0% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
PRME Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | -5800.5% | -4406.0% | -4787.2% | -3603.3% | N/A | -25948.3% |
| Net Margin | N/A | N/A | -5498.7% | -4129.1% | -4716.7% | -3568.8% | N/A | -25128.2% |
| Return on Equity | -105.8%-19.4pp | -64.0%-15.5pp | -38.1% | -31.3%-3.5pp | -86.4%-58.3pp | -48.5%-29.8pp | N/A | -27.7%-1.6pp |
| Return on Assets | -16.9%+1.9pp | -16.7%-0.9pp | -13.4% | -13.1%+2.6pp | -18.9%+2.4pp | -15.8%-1.1pp | N/A | -15.8%+5.4pp |
| Current Ratio | 3.05-0.5x | 3.80-1.0x | 4.84-0.7x | 6.61+0.1x | 3.56-4.7x | 4.78-4.1x | 5.58+3.0x | 6.50+1.8x |
| Debt-to-Equity | 5.26+1.7x | 2.84+0.8x | 1.84+0.9x | 1.38+0.6x | 3.58+3.3x | 2.07+1.8x | 0.94+0.5x | 0.76+0.5x |
| Asset Turnover | N/A | N/A | 0.00 | 0.000.0x | 0.000.0x | 0.000.0x | N/A | 0.000.0x |
| FCF Margin | N/A | N/A | -4480.4% | -2880.5% | -3855.1% | -3526.8% | N/A | -13009.1% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Prime Medicine PRME | FY2025 | $4.6M | -$201.1M | N/A | $665.7M | 57/100 |
| Vir Biotechnology, Inc. VIR | FY2025 | $68.6M | -$438.0M | N/A | $1.9B | 66/100 |
| Nurix Therapeutics, Inc. NRIX | FY2025 | $84.0M | -$264.5M | N/A | $2.7B | 53/100 |
| Praxis Precision Medicines, Inc. PRAX | FY2025 | $0 | -$303.0M | N/A | $10.0B | — |
| Arrivent Biopharma Inc AVBP | FY2025 | N/A | -$166.3M | N/A | $1.5B | — |
Where Prime Medicine Ranks
Frequently Asked Questions
What is Prime Medicine's annual revenue?
Prime Medicine (PRME) reported $4.6M in total revenue for fiscal year 2025. This represents a 55.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Prime Medicine's revenue growing?
Prime Medicine (PRME) revenue grew by 55.3% year-over-year, from $3.0M to $4.6M in fiscal year 2025.
Is Prime Medicine profitable?
No, Prime Medicine (PRME) reported a net income of -$201.1M in fiscal year 2025.
What is Prime Medicine's EBITDA?
Prime Medicine (PRME) had EBITDA of -$201.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Prime Medicine's return on equity (ROE)?
Prime Medicine (PRME) has a return on equity of -166.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Prime Medicine's free cash flow?
Prime Medicine (PRME) recorded an outflow of $167.1M in free cash flow during fiscal year 2025. This represents a -28.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Prime Medicine's operating cash flow?
Prime Medicine (PRME) recorded an outflow of $162.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Prime Medicine's total assets?
Prime Medicine (PRME) had $342.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Prime Medicine's capital expenditures?
Prime Medicine (PRME) invested $4.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Prime Medicine spend on research and development?
Prime Medicine (PRME) invested $160.6M in research and development during fiscal year 2025.
What is Prime Medicine's current ratio?
Prime Medicine (PRME) had a current ratio of 4.84 as of fiscal year 2025, which is generally considered healthy.
What is Prime Medicine's debt-to-equity ratio?
Prime Medicine (PRME) had a debt-to-equity ratio of 1.84 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Prime Medicine's return on assets (ROA)?
Prime Medicine (PRME) had a return on assets of -58.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Prime Medicine's P/E ratio?
Prime Medicine (PRME) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $665.7M as of Sep 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Prime Medicine's price-to-sales ratio?
Prime Medicine (PRME) trades at 144x sales, its market capitalization divided by revenue of $4.6M revenue, FY2025. The market capitalization is $665.7M as of Sep 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Prime Medicine's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Prime Medicine (PRME) held $177.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $162.6M over that year. Dividing the one by the other, the reported balance equals about 13 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Prime Medicine's Altman Z-Score?
Prime Medicine (PRME) has an Altman Z-Score of -3.32, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Prime Medicine's Piotroski F-Score?
Prime Medicine (PRME) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Prime Medicine's earnings high quality?
Prime Medicine (PRME) reported a net loss of $201.1M while operations used $162.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Prime Medicine?
Prime Medicine (PRME) scores 57 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.